ATG-031

N/A

Report date: 2024/03/21 15:56:18

Base Information

Drug NameATG-031
Drug Alias NameATG-031ATN-031
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Signal transducer CD24Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsMacrophages stimulants
TargetsSignal transducer CD24
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesAntengene Corporation Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corporation (Shanghai) LtdAntengene Corporation Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A